June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Potential of 5-HT3 receptor modulation for protection of light induced retinopathy
Author Affiliations & Notes
  • Renee C Ryals
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Shreya Datta
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Aaron Coyner
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Halkanae Gemechu
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Alex Chu
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Yuquan Wen
    Baylor Visual Function Center, Baylor University Medical Center, Dallas, TX
  • Mark E Pennesi
    Ophthalmology, Casey Eye Institute OHSU, Portland, OR
  • Footnotes
    Commercial Relationships Renee Ryals, None; Shreya Datta, None; Aaron Coyner, None; Halkanae Gemechu, None; Alex Chu, None; Yuquan Wen, None; Mark Pennesi, Sucampo (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 213. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Renee C Ryals, Shreya Datta, Aaron Coyner, Halkanae Gemechu, Alex Chu, Yuquan Wen, Mark E Pennesi; Potential of 5-HT3 receptor modulation for protection of light induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):213.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: 5-HT3 antagonists are widely used for antiemetic therapy and are being investigated as therapeutic options for a variety of behavioral disorders. Our previous results suggest that modulation of 5-HT1A and 5-HT2A receptors can protect the retina from light induced retinopathy. The purpose of this study was to determine if the serotonin 5-HT3 receptor is located in the retina and if modulation of the receptor protects the retina from light induced retinopathy.

Methods: Total membrane protein and plasma membrane protein was extracted from C57BL/6 retinas. SDS-PAGE electrophoresis was performed and blots were probed with an antibody specific to 5-HT3A (Alomone Labs). To test if 5-HT3 receptor modulation is neuroprotective, two-month-old BALB/c mice were placed in a 12/12 hour alternate light-dark cycle room. For induction of retinopathy, dark-adapted mice were placed in a custom light-damage box with 4 CFL bulbs (42 watts, 6500K color temperature). Mice were exposed to 10,000 lux of light for 1-hour. Palonosetron (0.2 mg/kg), a 5-HT3 antagonist, and m-Chlorophenylbiguanide (m-CPBG) (10 mg/kg), a 5-HT3 agonist, were injected intraperitoneally 48 hours, 24 hours and 0 hours prior to bright light exposure as well as 24 hours and 48 hours after bright light exposure. To evaluate neuroprotection, linear scans of the retina were acquired using spectral domain-optical coherence tomography (Bioptigen, Inc.). Retinal thickness was quantified on manually segmented images using custom software written in IGOR Pro. Retinal function was measured by full-field electroretinogram.

Results: Western blots demonstrated 5-HT3 receptor expression in total membrane and plasma membrane protein extract from mouse retina. SD-OCT images showed no preservation of the outer nuclear layer in palonosetron and m-CPBG injected mice. In addition, maximum scotopic a-wave and b-wave amplitudes of palonosetron and m-CPBG injected mice were not statistically different (p<0.05) from saline injected mice.

Conclusions: 5-HT3 receptors are present in the retina. However, intraperitoneal injection with a selective 5-HT3 agonist, m-CPBG, or a selective antagonist, palonosetron, did not result in neuroprotection. This does not provide evidence that the 5-HT3 ligand-gated ion channel plays a role in neuroprotection. Neuroprotection observed by 5-HT modulators may be G protein-coupled receptor specific.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×